AYLA
Income statement / Annual
Last year (2022), Ayala Pharmaceuticals, Inc.'s total revenue was $692.00 K,
and the percentage change from the previous year is not available.
In 2022, Ayala Pharmaceuticals, Inc.'s net income was -$38.01 M.
See Ayala Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$692.00 K |
$0.00 |
$3.71 M |
$2.33 M |
$0.00 |
| Cost of Revenue |
$602.00 K
|
$3.51 M
|
$3.71 M
|
$1.29 M
|
$0.00
|
| Gross Profit |
$90.00 K
|
-$3.51 M
|
$0.00
|
$1.05 M
|
$0.00
|
| Gross Profit Ratio |
0.13
|
0
|
0
|
0.45
|
0
|
| Research and Development Expenses |
$27.85 M
|
$29.94 M
|
$22.41 M
|
$14.42 M
|
$5.74 M
|
| General & Administrative Expenses |
$9.74 M
|
$9.28 M
|
$7.37 M
|
$4.34 M
|
$3.29 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.74 M
|
$9.28 M
|
$7.37 M
|
$4.34 M
|
$3.29 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$37.59 M
|
$39.22 M
|
$29.78 M
|
$18.76 M
|
$9.04 M
|
| Cost And Expenses |
$38.20 M
|
$42.72 M
|
$33.49 M
|
$20.05 M
|
$9.04 M
|
| Interest Income |
$0.00
|
$0.00
|
$56.00 K
|
$225.00 K
|
$448.00 K
|
| Interest Expense |
-$74.00 K
|
-$1.55 M
|
$56.00 K
|
$225.00 K
|
$0.00
|
| Depreciation & Amortization |
$162.00 K
|
$168.00 K
|
$182.00 K
|
$150.00 K
|
$49.00 K
|
| EBITDA |
-$37.34 M |
-$40.86 M |
-$29.48 M |
-$17.11 M |
-$8.54 M |
| EBITDA Ratio |
-53.96
|
0
|
-7.95
|
-7.33
|
0
|
| Operating Income Ratio |
-54.2
|
0
|
-8.03
|
-7.59
|
0
|
| Total Other Income/Expenses Net |
$74.00 K
|
$3.25 M
|
$56.00 K
|
$225.00 K
|
$448.00 K
|
| Income Before Tax |
-$37.43 M
|
-$39.48 M
|
-$29.72 M
|
-$17.49 M
|
-$8.59 M
|
| Income Before Tax Ratio |
-54.09
|
0
|
-8.02
|
-7.49
|
0
|
| Income Tax Expense |
$584.00 K
|
-$776.00 K
|
$425.00 K
|
$306.00 K
|
$286.00 K
|
| Net Income |
-$38.01 M
|
-$38.70 M
|
-$30.15 M
|
-$17.79 M
|
-$8.87 M
|
| Net Income Ratio |
-54.93
|
0
|
-8.13
|
-7.62
|
0
|
| EPS |
-2.46 |
-3.92 |
-3.06 |
-2.07 |
-1.31 |
| EPS Diluted |
-2.46 |
-3.92 |
-3.06 |
-2.07 |
-1.31 |
| Weighted Average Shares Out |
$15.45 M
|
$9.86 M
|
$9.86 M
|
$8.58 M
|
$6.77 M
|
| Weighted Average Shares Out Diluted |
$15.45 M
|
$9.86 M
|
$9.86 M
|
$8.58 M
|
$6.77 M
|
| Link |
|
|
|
|
|
